EcoDrugPlus

Matrix Metalloproteinase-9-Like

Ensembl ID : ENSPFOG00000001343
Gene Symbol: LOC103129676
3 Cross references
202 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSPFOG00000008483
Gene Symbol: MTOR
3 Cross references
216 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSPFOG00000020977
Gene Symbol: LOC103146926
3 Cross references
89 Possible Orthologues:

Melanocyte-Stimulating Hormone Receptor

Ensembl ID : ENSPFOG00000020598
Gene Symbol: LOC103136569
3 Cross references
159 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase

Ensembl ID : ENSPFOG00000005185
Gene Symbol: LOC103156750
2 Cross references
215 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSPFOG00000023633
Gene Symbol: MTNR1A
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSPFOG00000008478
Gene Symbol: MME
2 Cross references
230 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSPFOG00000008421
Gene Symbol: MME
2 Cross references
230 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSPFOG00000016927
Gene Symbol: LOC103138398
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSPFOG00000018558
Gene Symbol: LOC103133774
3 Cross references
215 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSPFOG00000017347
Gene Symbol: LOC103140495
3 Cross references
211 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSPFOG00000013223
Gene Symbol: METAP2
4 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).